1. Home
  2. KR vs ILMN Comparison

KR vs ILMN Comparison

Compare KR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kroger Company (The)

KR

Kroger Company (The)

N/A

Current Price

$61.57

Market Cap

34.9B

ML Signal

N/A

Logo Illumina Inc.

ILMN

Illumina Inc.

N/A

Current Price

$225.16

Market Cap

32.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KR
ILMN
Founded
1883
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.9B
32.3B
IPO Year
2007
2000

Fundamental Metrics

Financial Performance
Metric
KR
ILMN
Price
$61.57
$225.16
Analyst Decision
Buy
Hold
Analyst Count
12
17
Target Price
$74.25
$124.24
AVG Volume (30 Days)
6.2M
1.8M
Earning Date
03-05-2026
04-30-2026
Dividend Yield
2.09%
N/A
EPS Growth
N/A
170.87
EPS
1.46
2.22
Revenue
$147,642,000,000.00
$4,343,000,000.00
Revenue This Year
$4.39
$6.47
Revenue Next Year
$2.30
$5.58
P/E Ratio
$42.67
$100.13
Revenue Growth
0.35
N/A
52 Week Low
$54.15
$88.00
52 Week High
$76.58
$231.81

Technical Indicators

Market Signals
Indicator
KR
ILMN
Relative Strength Index (RSI) 67.57 60.72
Support Level $61.17 $117.73
Resistance Level $64.44 $231.81
Average True Range (ATR) 1.51 8.27
MACD 0.43 -1.03
Stochastic Oscillator 96.44 70.06

Price Performance

Historical Comparison
KR
ILMN

About KR Kroger Company (The)

Founded in 1883, Kroger is the largest pure-play supermarket operator in the United States, operating roughly 2,700 stores across more than 30 banners. Kroger's business is primarily grocery-led (roughly 78% of sales), spanning fresh food and private-label offerings, complemented by fuel centers (9%) and pharmacies (12%). The firm also generates income from advertising, data analytics, and manufacturing.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: